---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-23-000024"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:27:51.634400+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xencor Q2 2023 revenue $45.5M up 51% YoY; net loss narrows to $22M; pipeline advances

## Summary
- Revenue $45.5M (vs $30.2M Q2 2022), net loss $22.0M ($0.37/diluted) vs $34.0M loss ($0.57) prior.
- Cash, equivalents and marketable securities $531.4M at June 30, 2023, down from $613.5M at Dec 31, 2022.
- Royalty revenue from Alexion's Ultomiris $11.2M; $10M milestone from Zenas for obexelimab Phase 3 start.
- R&D expenses $60.1M, up 28% YoY; guidance projects year-end cash $425-475M, funding through 2025.
- Vudalimab Phase 2 front-line NSCLC expected by year-end; XmAb662 Phase 1 started; XmAb541 IND planned.

## SEC filing metadata
- accession: 0001326732-23-000024
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000024/0001326732-23-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000024/xncr-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-23-000024
- JSON: https://secwatch.observer/filing/0001326732-23-000024.json
- Plain text: https://secwatch.observer/filing/0001326732-23-000024.txt

## Key facts
- Earnings Releases
  Xencor Inc reported second quarter ended June 30, 2023 results: revenue $45.5 million.
  - Period: second quarter ended June 30, 2023
  - Revenue: $45.5 million
  - Result: reported results
  source text: Total revenue for the second quarter ended June 30, 2023 was $45.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000024/0001326732-23-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.